Novel MicroRNA-Regulated Transcript Networks Are Associated with Chemotherapy Response in Ovarian Cancer

Int J Mol Sci. 2022 Apr 28;23(9):4875. doi: 10.3390/ijms23094875.

Abstract

High-grade serous ovarian cancer (HGSOC) is a highly lethal gynecologic cancer, in part due to resistance to platinum-based chemotherapy reported among 20% of patients. This study aims to generate novel hypotheses of the biological mechanisms underlying chemotherapy resistance, which remain poorly understood. Differential expression analyses of mRNA- and microRNA-sequencing data from HGSOC patients of The Cancer Genome Atlas identified 21 microRNAs associated with angiogenesis and 196 mRNAs enriched for adaptive immunity and translation. Coexpression network analysis identified three microRNA networks associated with chemotherapy response enriched for lipoprotein transport and oncogenic pathways, as well as two mRNA networks enriched for ubiquitination and lipid metabolism. These network modules were replicated in two independent ovarian cancer cohorts. Moreover, integrative analyses of the mRNA/microRNA sequencing and single-nucleotide polymorphisms (SNPs) revealed potential regulation of significant mRNA transcripts by microRNAs and SNPs (expression quantitative trait loci). Thus, we report novel transcriptional networks and biological pathways associated with resistance to platinum-based chemotherapy in HGSOC patients. These results expand our understanding of the effector networks and regulators of chemotherapy response, which will help to improve the management of ovarian cancer.

Keywords: The Cancer Genome Atlas; coexpression network analysis; differential expression analysis; expression quantitative trait loci; high-grade serous ovarian cancer; microRNAs; platinum-based chemotherapy resistance.

MeSH terms

  • Carcinoma, Ovarian Epithelial / drug therapy
  • Drug Resistance, Neoplasm / genetics
  • Female
  • Gene Regulatory Networks* / drug effects
  • Gene Regulatory Networks* / genetics
  • Humans
  • MicroRNAs* / genetics
  • MicroRNAs* / therapeutic use
  • Ovarian Neoplasms* / drug therapy
  • Ovarian Neoplasms* / genetics
  • Platinum / therapeutic use
  • RNA, Messenger / genetics

Substances

  • MicroRNAs
  • RNA, Messenger
  • Platinum